Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed.

1. Hypothalamic AMPK and energy balance.European journal of clinical investigation · 2018
   Review
2. EJE PRIZE 2017: Hypothalamic AMPK: a golden target against obesity?European journal of endocrinology · 2017
   Review
3. Antidiabetic effect of Sida cordata in alloxan induced diabetic rats.BioMed research international · 2014
   Article
4. Disruption of inducible 6-phosphofructo-2-kinase impairs the suppressive effect of PPARγ activation on diet-induced intestine inflammatory response.The Journal of nutritional biochemistry · 2013
   Article
5. Oral Hypoglycemic Agents in pregnancy: An Update.Journal of obstetrics and gynaecology of India · 2013
   Review
6. Rosiglitazone: trials, tribulations and termination.Drugs · 2011
   Article
7. Involvement of inducible 6-phosphofructo-2-kinase in the anti-diabetic effect of peroxisome proliferator-activated receptor gamma activation in mice.The Journal of biological chemistry · 2010
   Article
8. Is cytochrome modulation the new frontier for decreasing the risk of cataract?Indian journal of pharmacology · 2009
   Article
9. New drugs for type 2 diabetes mellitus: what is their place in therapy?Drugs · 2008
   Review
10. Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK.PharmacoEconomics · 2006
    Review
11. Oral antidiabetic agents: current role in type 2 diabetes mellitus.Drugs · 2005
    Review
12. Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity.Journal of endocrinological investigation · 2004
    Review
13. Reimbursement of glitazones in treatment of type 2 diabetes patients in Denmark in the context of a voluntary system for submitting pharmacoeconomic studies.The European journal of health economics : HEPAC : health economics in prevention and care · 2004
    Article
14. Thiazolidinediones for type 2 diabetes. No evidence exists that pioglitazone induces hepatic cytochrome P450 isoform CYP3A4.BMJ (Clinical research ed.) · 2001
    Article
15. Optimising therapy for insulin-treated type 2 diabetes mellitus.Drugs & aging · 2000
    Review

Corrections and comments

• Commented on by
  Thiazolidinediones for type 2 diabetes. No evidence exists that pioglitazone induces hepatic cytochrome P450 isoform CYP3A4.2001
• Commented on by
  Thiazolidinediones for type 2 diabetes. All glitazones may exacerbate heart failure.2001

Authors and funding

3 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as